Last reviewed 2026-04-23 · How we verify

GP681

GP681 is a small molecule drug that targets the SGLT2 receptor.

GP681 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Mechanism of action

GP681 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.

Approved indications

• Type 2 diabetes

Common side effects

• Nausea
• Diarrhea
• Vomiting

Key clinical trials

• Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension (PHASE1)
• Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects (PHASE1)
• Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza (PHASE3)
• Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications (PHASE3)
• GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers (PHASE1)
• To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection (PHASE3)
• A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers (PHASE1)
• A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.